Introduction
============

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system of autoimmune etiopathogenesis, and is characterized by neurological symptoms ([@b1-mmr-20-01-0678]). A total of \~90% of patients with MS are diagnosed with relapsing-remitting disease, that involve acute periods of neurological dysfunctions followed by a period of recovery ([@b2-mmr-20-01-0678]). Glatiramer acetate and interferon-β (IFN-β) are administered as first-line therapies. In patients non-responsive to treatment, several second-line therapies are available, including natalizumab and fingolimod ([@b3-mmr-20-01-0678]). Natalizumab is a monoclonal antibody against the α4 subunit (CD49d) of α4 integrins \[α4β1 (VLA-4) and α4β7), that prevents the transmigration of leukocytes across the blood-brain barrier by inhibiting interactions between α4β1 integrin/vascular cell adhesion molecule-1 and mucosal vascular addressin cell adhesion molecule-1 ([@b4-mmr-20-01-0678]). In 2012, a longitudinal study assessing the effects of natalizumab on 333 patients with MS revealed that 69--88% of patients exhibited a positive outcome in all Patient-Reported Outcomes measures assessed ([@b5-mmr-20-01-0678]). In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) trial ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT00027300), of 942 patients, 627 were randomly selected for treatment with natalizumab and 315 were administered a placebo. The results revealed that natalizumab reduced the risk of sustained disability progression by 42% in a 2-year time-frame and decreased the rate of clinical relapse in 1 year by 68%, leading to an 83% reduction in the accumulation of new or enlarging T-2 hyperintense lesions ([@b6-mmr-20-01-0678]). Additionally, the results of a SENTINEL trial indicated that 67% of patients receiving natalizumab plus IFN-β-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFN-β-1a alone ([@b7-mmr-20-01-0678]). These findings indicate that despite the high efficacy, a percentage of patients with MS do not respond, or respond partially to natalizumab. Therefore, it is of the utmost importance to develop a diagnostic test to predict drug response in patients suffering from complex diseases, such as MS, in which several therapeutic options are readily available. This could lead to a double-fold advantage: Patients would benefit by avoiding ineffective therapies and healthcare costs would be notably reduced. In the present study, a machine learning approach was utilized to identify a subset of genes that may predict the response of patients with MS to natalizumab prior to the initiation of therapy.

Materials and methods
=====================

### Molecular patterns of pharmacological resistance to natalizumab

For the identification of the molecular patterns underlying the pharmacological resistance to natalizumab in MS, we selected the GSE44964 microarray dataset, available from the Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/>). The dataset comprised whole-genome expression data from CD4^+^ T cells isolated from patients with MS and stimulated *in vitro* with precoated anti-CD3/-CD28 monoclonal antibodies for 48 h. The Agilent Sureprint G3 Human Gene Expression 8×60k platform was used to generate the dataset (Agilent Technologies, Inc., Santa Clara, CA, USA). The raw data were quantile normalized and batch effect-corrected using ComBat v2 ([@b8-mmr-20-01-0678]). The patients were of Swedish origin and had relapsing-remitting disease. The GSE44964 dataset comprises data generated from two different microarray platforms. To avoid obtaining biased results, the data of two platforms were not combined; thus, analysis was conducted using the largest set of samples only. Patients were diagnosed with MS according to the McDonald criteria ([@b9-mmr-20-01-0678]) and prospectively classified as low responders (LRs, n=6), if at least one period of relapse occurred during the follow-up period (3 years) and as high responders (HRs, n=6), providing no relapse was observed. Other parameters, such as magnetic resonance imaging could be used for the classification of LRs and HRs; however, the relapse rate is considered as a primary endpoint of several phase 2/3 clinical trials ([@b6-mmr-20-01-0678]), and classifying patients as responsive and non-responsive on the basis of whether relapse had occurred or not is appropriate for a preliminary transcriptomic analysis. All samples were collected for gene expression analysis prior to the initiation of natalizumab treatment. The LR and HR groups were matched for sex, age, Expanded Disability Status Scale score ([@b10-mmr-20-01-0678]) and disease duration ([@b11-mmr-20-01-0678]). A total of 5/6 patients in the groups were males; the age of patients was 36±6.3 and 33.7±7.1 years old for LRs and HRs, respectively. Statistical differences between HR and LR patients were assessed using LIMMA version 3.26.8 (Linear models for microarray data) in R version 3.2.3 ([@b12-mmr-20-01-0678]). P\<0.01 was considered to indicate a statistically significant difference. Statistical analysis and principal component analysis (PCA) were performed using MultiExperiment Viewer software (<http://mev.tm4.org/>). Gene Ontology (GO) analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 web-based tool ([@b13-mmr-20-01-0678],[@b14-mmr-20-01-0678]). Functional annotation provided by DAVID comprises \>40 annotation categories, including GO terms, protein-protein interactions, protein domains, disease associations, pathways, homology, gene function, gene tissue expression and literature. Network analysis was performed using the GeneMania utility ([@b15-mmr-20-01-0678]).

### Identification of biomarkers for natalizumab responsiveness

In order to identify a specific gene expression signature for predicting patient responsiveness to natalizumab treatment, the UnCorrelated Shrunken Centroid (UCSC; <http://home.cc.umanitoba.ca/~psgendb/birchhomedir/BIRCHDEV/doc/MeV/manual/usc.html>) algorithm was used. UCSC analysis was performed with the probes that were determined to be significantly modulated in HRs compared with the LR group. Cross-validation was conducted using the following parameters: 5-fold and 10-fold cross-validation; each cross-validation run was divided five-fold and therefore, a total 10 cross-validation runs were performed. Δ-(shrinkage threshold) and ρ-(correlation threshold) values were empirically selected so that the smallest number of classification errors were obtained using the fewest genes. Subsequently, PCA and Hierarchical Clustering (HCL) was performed using only the set of the identified predictors. For HCL, Euclidean distance and average linkage degree were used.

Results
=======

### HR and LR patients have different transcriptomic patterns

Statistical analysis of the transcriptomic differences between CD4^+^ T cells from patients of the HR and LR groups revealed 45 significant probes ([Table I](#tI-mmr-20-01-0678){ref-type="table"}). PCA ([Fig. 1A](#f1-mmr-20-01-0678){ref-type="fig"}) produced two main clusters that contained HRs and LRs, respectively. The results indicated that the mRNA expression levels of several genes notably differed between natalizumab-responsive and non-responsive patients, and that a distinct pattern of gene expression could be associated with natalizumab resistance. Functional annotation revealed that the most enriched categories and their associated genes were: 'Lipid-binding' \[oxysterol binding protein like 6 (OSBPL6), fatty acid binding protein 3 (FABP3), estrogen receptor 1 (ESR1) and sorting nexin 10 (SNX10)\], 'estrogen-responsive protein Efp controls cell cycle and breast tumors growth' \[ESR1 and stratifin (SFN)\], 'cytoplasm' \[OSBPL6, ESR1, SFN, amyloid β precursor-like protein 1 (APLP1), inorganic pyrophosphatase PPA1), tropomyosin 3 (TPM3), 20S proteasome subunit β-2 (PSMB7), RAB28, member RAS oncogene family (RAB28), regulator of G-protein signaling 5, FABP3, TBC1 domain family member 32 (TBC1D32), SNX10 and coiled-coil domain-containing protein 8\] and 'protein localization to cilium' (SNX10 and TBC1D32) ([Fig. 1B](#f1-mmr-20-01-0678){ref-type="fig"}). A regulatory network comprising the significant genes and the top 20 related genes, was presented as [Fig. 1C](#f1-mmr-20-01-0678){ref-type="fig"}. The computational gene network prediction tool GeneMania identified the DNA topoisomerase II α gene to interact with PPA1, TNFAIP3 interacting protein 3, PSMB3, RAB28, APLP1, ESR1 and ring finger protein 113A. Other nodes were represented by PSMB7, alanyl-tRNA synthetase, APLP1 and ESR1 ([Fig. 1C](#f1-mmr-20-01-0678){ref-type="fig"}).

### Machine learning-identified genes for predicting natalizumab responsiveness

To identify a specific gene signature for natalizumab responsiveness, the UCSC algorithm was applied to the significant probes identified. The following parameters were selected: Δ=1 and ρ=1 for UCSC analysis. A total of 17 predictors of the 45 probes ([Fig. 2A](#f2-mmr-20-01-0678){ref-type="fig"}) were identified from UCSC analysis that were able to classify HR and LR samples with 89.2% agreement with the clinical data ([Fig. 2B](#f2-mmr-20-01-0678){ref-type="fig"}). Consistent with these findings, HCL and PCA based on the 17 markers were able to accurately separate HR and LR patients ([Fig. 2C and D](#f2-mmr-20-01-0678){ref-type="fig"}). The 17 identified predictors were presented in [Table II](#tII-mmr-20-01-0678){ref-type="table"}.

Discussion
==========

Several studies have investigated expression array phenotyping as a means for predicting drug response and clinical prognosis ([@b16-mmr-20-01-0678]--[@b18-mmr-20-01-0678]), and for the classification of diseases ([@b18-mmr-20-01-0678]--[@b25-mmr-20-01-0678])the most common lymphoid malignancy in adults, is curable in less than 50% of patients. Prognostic models based on pre-treatment characteristics, such as the International Prognostic Index (IPI. Predicting diagnostic classes based on a sample using its expression profile is known as supervised learning or classification. The use of microarray data, although practical, poses the problem of predicting diagnostic classes using a number of genes that is notably higher than the number of sample types available. Therefore, it is necessary to select subsets of genes that are relevant for the characterization of the different diagnostic classes. In addition, the identification of specific subsets of genes may improve the classification accuracy, allow the development of cost-effective diagnostic tests and may provide novel biological insight into certain diseases. Classification can be defined as a supervised learning approach, in which the classes of a series of samples are inputted to an algorithm. This is distinct from unsupervised clustering, in which no prior knowledge of the samples is available. The aim of classification is to identify the smallest possible subgroup of genes highly associated with the known sample classes. The UCSC algorithm is based on the 'Shrunken Centroid' algorithm reported by Tibshirani *et al* ([@b25-mmr-20-01-0678]). Briefly, genes are considered one at a time and the difference between the class centroid (the mean expression in a class) of a gene and the overall centroid (the mean expression level across all classes) of a gene is compared with the within-class standard deviation plus a Δ-value, which is determined by cross-validation, in order to minimize classification errors. In the present study, the UCSC algorithm was applied for the identification of a subset of genes that could predict the pharmacological response to natalizumab treatment among patients with relapsing-remitting MS. Natalizumab is a disease-modifying drug that can effectively reduce the frequency of relapse and short-term disability progression in relapsing-remitting MS, and it is often used as second-line treatment in patients exhibiting active disease, despite treatment with glatiramer acetate or IFN-β ([@b26-mmr-20-01-0678]).

To the best of our knowledge, the present study is the first to identify, at the whole-genome level, the genes that were significantly modulated in HR patients compared with the LR group. Our findings suggest that a specific gene expression profile of CD4^+^ T cells may characterize the pharmacological responsiveness to natalizumab in patients with MS. Interestingly, no significant differences in the transcription levels of CD49d and CD29, which encode the target of natalizumab comprising the α4 and β1 subunits of VLA-4, were observed between the HR and LR groups of patients (data not shown). Additionally, we applied machine learning to select the minimum number of genes able to predict the response to natalizumab. The results indicate the genes that may be relevant for P4 medicine, which constitutes predictive, preventative, personalized and participatory medicine ([@b27-mmr-20-01-0678]). At present, the mechanisms of resistance to natalizumab remains largely unknown. Recently, Cavaliere *et al* ([@b28-mmr-20-01-0678]) applied molecular dynamics simulation to determine whether a polymorphism could induce conformational changes in VLA-4, affecting the binding affinity with natalizumab; expression profiling of circulating blood cells should be conducted for the identification of biomarkers of natalizumab resistance. The role of the genes identified in our study requires further investigation; however, certain genes may be involved in immunity and the pathology of MS. In particular, the Ras-related protein, Rab-28, has been detected in the serum of Alzheimer\'s disease and MS patients ([@b29-mmr-20-01-0678]). TPM3 was determined to be phosphorylated following T cell costimulation, resulting in downregulated interleukin-2-stimulated T cells ([@b30-mmr-20-01-0678]). The locus 3 kb upstream of the zinc finger 57, that encodes a protein likely to act as a transcriptional repressor, has been reported to be hypomethylated in CD4^+^ T cells from patients with MS compared with healthy controls ([@b31-mmr-20-01-0678]). Increasing efforts are required to validate our findings determine of the role of the genes involved.

The use of biomarkers to predict natalizumab resistance in MS would lead to notable therapeutic and economic benefits; however, our study has several limitations. The number of patients is limited and no external validation could be performed. In addition, it has not been disclosed by the original authors of the microarray datasets whether natalizumab treatment was administered as first-line therapy or after failure with other medications, such as glatiramer acetate or IFN-β. Furthermore, a comparison with other second-line drugs, such as fingolimod, should be conducted. Finally, the expression profiles of unsorted and unstimulated circulating cell populations, such as whole blood cells or peripheral blood mononuclear cells should be determined for the development of simple and economically viable diagnostic tests. Despite these limitations of the present study, findings may serve as a basis for the design of personalized therapeutic options for patients with MS.
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![Molecular patterns of pharmacological resistance to natalizumab. For the identification of the molecular patterns underlying the pharmacological resistance to natalizumab in MS, we selected the GSE44964 microarray dataset that included expression data from CD4^+^ T cells isolated from patients with MS, which were stimulated *in vitro* with anti-CD3/-CD28 monoclonal antibodies for 48 h. Statistical differences between HR (n=6) and LR (n=6) patients were assessed using LIMMA. (A) Principal component analysis was performed using MultiExperiment Viewer software and the genes significantly modulated between HR and LR patients. The distribution of the samples of the first two components was presented. (B) Gene Ontology analysis for the genes significantly modulated between HR and LR patients was performed using the Database for Annotation, Visualization and Integrated Discovery v6.8 web-based tool. (C) Network analysis for genes significantly modulated between HR and LR patients was performed using the GeneMania. HR, high responder; LR, low responder; NF-κB, nuclear factor-κB.](MMR-20-01-0678-g00){#f1-mmr-20-01-0678}

![Prediction of pharmacological response to natalizumab. In order to determine a specific gene expression signature for predicting responsiveness to natalizumab treatment, the UCSC algorithm was applied to the genes significantly modulated between HR and LR patients. (A) The experimental procedure. (B) The number of classification errors obtained from UCSC analysis using different Δ-values (C) Hierarchical clustering of the 17 predictor genes obtained via UCSC analysis. (D) Principal component analysis using the 17 predictor genes obtained via UCSC analysis. The distribution of the samples on the first three components. HR, high responder; LR, low responder; UCSC, UnCorrelated Shrunken Centroid.](MMR-20-01-0678-g01){#f2-mmr-20-01-0678}

###### 

List of genes significantly modulated between LRs and HRs CD4^+^ T cells.

  Probe            Gene accession no.   Gene symbol    Gene name                                                                           P-value   Log fold change
  ---------------- -------------------- -------------- ----------------------------------------------------------------------------------- --------- -----------------
  A_19_P00317412                        XLOC_000787                                                                                        0.0048    −0.4088
  A_19_P00317731                        XLOC_002473                                                                                        0.0078    0.6845
  A_19_P00319311                                                                                                                           0.0046    0.6016
  A_19_P00321466                                                                                                                           0.0079    0.5516
  A_19_P00805263                        XLOC_001851                                                                                        0.0088    0.3698
  A_19_P00807336                                                                                                                           0.0030    −0.5004
  A_23_P108823     NM_032523            OSBPL6         Oxysterol binding protein-like 6                                                    0.0054    −0.3303
  A_23_P112187     NM_032843            FIBCD1         Fibrinogen C domain containing 1                                                    0.0059    −1.1805
  A_23_P164958     NM_032040            CCDC8          Coiled-coil domain containing 8                                                     0.0044    0.6849
  A_23_P27983      NM_005166            APLP1          Amyloid β (A4) precursor-like protein 1                                             0.0077    −0.7417
  A_23_P381017     NM_152559            WBSCR27        Williams Beuren syndrome chromosome region 27                                       0.0051    0.8273
  A_23_P386478     NM_024873            TNIP3          TNFAIP3 interacting protein 3                                                       0.0065    −0.9948
  A_23_P398172     NM_020819            FAM135A        Family with sequence similarity 135, member A                                       0.0099    0.7579
  A_23_P401547     NM_015480            PVRL3          Poliovirus receptor-related 3                                                       0.0076    0.4645
  A_23_P54205      NM_017926            C14orf118      Chromosome 14 open reading frame 118                                                0.0067    0.6402
  A_23_P77135      NM_080650            ATPBD4         ATP binding domain 4                                                                0.0084    1.0763
  A_23_P90523      NM_024578            OCEL1          Occludin/ELL domain containing 1                                                    0.0025    −0.3799
  A_24_P62783      NM_004102            FABP3          Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)   0.0016    −0.6532
  A_24_P920048     AK092807             LOC100127972   Uncharacterized LOC100127972                                                        0.0043    0.9088
  A_32_P204376     NM_001012421         ANKRD20A2      Ankyrin repeat domain 20 family, member A2                                          0.0084    0.3258
  A_32_P7204       NM_004249            RAB28          RAB28, member RAS oncogene family                                                   0.0057    0.8683
  A_32_P797019     XM_003403482         NPEPL1         Aminopeptidase-like 1                                                               0.0060    0.6953
  A_32_P80245      NM_001109809         ZFP57          Zinc finger protein 57 homolog (mouse)                                              0.0042    1.0614
  A_33_P3221925    NM_152730            C6orf170       Chromosome 6 open reading frame 170                                                 0.0018    0.6414
  A_33_P3227269    NR_024256            FLJ45983       Uncharacterized LOC399717                                                           0.0047    0.9719
  A_33_P3231297    NM_003851            CREG1          Cellular repressor of E1A-stimulated genes 1                                        0.0073    −0.3014
  A_33_P3233273    NM_001142928         LRRC61         Leucine rich repeat containing 61                                                   0.0067    0.4877
  A_33_P3243093    NM_003617            RGS5           Regulator of G-protein signaling 5                                                  0.0042    −0.7003
  A_33_P3271241    NM_021129            PPA1           Pyrophosphatase (inorganic) 1                                                       0.0079    −0.3602
  A_33_P3273552    NM_002282            KRT83          Keratin 83                                                                          0.0004    −0.9603
  A_33_P3289536    NM_001199835         SNX10          Sorting nexin 10                                                                    0.0082    0.9177
  A_33_P3292724    BC017576                                                                                                                0.0042    0.6890
  A_33_P3333600                         LOC400950      Uncharacterized LOC400950                                                           0.0078    −0.6855
  A_33_P3338674    NR_033298            CCDC163P       Coiled-coil domain containing 163, pseudogene                                       0.0006    −1.1794
  A_33_P3341474    NM_001080412         ZBTB38         Zinc finger and BTB domain containing 38                                            0.0067    0.7430
  A_33_P3346193    NM_001043351         TPM3           Tropomyosin 3                                                                       0.0022    0.8160
  A_33_P3354514    BC047507             SLC2A13        Solute carrier family 2 (facilitated glucose transporter), member 13                0.0004    0.4126
  A_33_P3379356    NM_001122742         ESR1           Estrogen receptor 1                                                                 0.0062    0.5516
  A_33_P3382489                                                                                                                            0.0056    0.6209
  A_33_P3387110    NR_015419            LOC145783      Uncharacterized LOC145783                                                           0.0081    −0.5672
  A_33_P3389286    NM_006142            SFN            Stratifin                                                                           0.0059    0.7813
  A_33_P3400292                                                                                                                            0.0094    −0.5263
  A_33_P3407429                         PSMB7          Proteasome (prosome, macropain) subunit, β type, 7                                  0.0052    −0.4364
  A_33_P3541279    AF116649                                                                                                                0.0021    0.8729
  A_33_P3876414    AJ272176             C17orf6        Chromosome 17 open reading frame 6                                                  0.0090    0.5759

###### 

Predictors of natalizumab responsiveness.

  Probe           Gene accession no.   Gene symbol    Description
  --------------- -------------------- -------------- -----------------------------------------------------------------------------------
  A_33_P3273552   NM_002282            KRT83          Keratin 83
  A_33_P3338674   NR_033298            CCDC163P       Coiled-coil domain containing 163, pseudogene
  A_24_P62783     NM_004102            FABP3          Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)
  A_33_P3221925   NM_152730            C6orf170       Chromosome 6 open reading frame 170
  A_33_P3541279   AF116649                            
  A_33_P3346193   NM_001043351         TPM3           Tropomyosin 3
  A_33_P3243093   NM_003617            RGS5           Regulator of G-protein signaling 5
  A_32_P80245     NM_001109809         ZFP57          Zinc finger protein 57 homolog (mouse)
  A_24_P920048    AK092807             LOC100127972   Uncharacterized LOC100127972
  A_33_P3227269   NR_024256            FLJ45983       Uncharacterized LOC399717
  A_23_P381017    NM_152559            WBSCR27        Williams Beuren syndrome chromosome region 27
  A_32_P7204      NM_004249            RAB28          RAB28, member RAS oncogene family
  A_23_P112187    NM_032843            FIBCD1         Fibrinogen C domain containing 1
  A_33_P3389286   NM_006142            SFN            Stratifin
  A_23_P386478    NM_024873            TNIP3          TNFAIP3 interacting protein 3
  A_33_P3289536   NM_001199835         SNX10          Sorting nexin 10
  A_23_P77135     NM_080650            ATPBD4         ATP binding domain 4
